Skip to main content

Advertisement

SpringerLink
Log in

The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Introduction

Although several clinical factors which show the benefit of adjuvant chemotherapy (AC) in early-stage colon cancer use for evaluating the risk of relapse, there is no consensus on which risk factors are more reliable. In this study, we evaluated both the utility of MSI and the daily practice of the Turkish oncologists in stage II and III colon cancer.

Material and Method

We conducted an online questionnaire which was consisting of twenty questions including the treatment choices and duration about stage II–III colon cancer depending on sidedness and risk factors for relapse.

Results

More than 65% of the oncologists declared the use of MSI testing in stage II colon cancer without considering any risk factors. In stage 3 colon cancer oncologists had an equal decision “to do or not to do” in MSI testing.

More than 50% of the oncologists had preferred XELOX protocol in high-risk stage II (T4N0) colon cancer, while three out of four preferred observation in low-risk stage II (T3N0) patients without risk factors. Two-thirds of the oncologists had preferred 6 months of treatment in stage II colon cancer with at least one risk factor.

Conclusion

Turkish oncologists participating to this trial had declared conflicting results about adjuvant treatment in early-stage colorectal cancer in their daily practice compared with the updated guidelines, especially, MSI evaluation utility in stage III colon cancers, adjuvant chemotherapy (AC) duration, and oxaliplatin adding to AC in elderly and stage II patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol 2004;22(16):3395–407. https://doi.org/10.1200/JCO.2004.03.087.

  2. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797–806.

    Article  CAS  Google Scholar 

  3. Schmoll HJ, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol [Internet]. 2015/08/31. United States; 2015;33:3733–40. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26324362

  4. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.

    Article  Google Scholar 

  5. Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol [Internet]. 2007/04/30. United States; 2007;25:2198–204. Available from: https://www.ncbi.nlm.nih.gov/pubmed/17470851

  6. Bergquist JR, Thiels CA, Spindler BA, Shubert CR, Hayman AV, Kelley SR, et al. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database. Dis Colon Rectum. 2016;59:1142–9.

    Article  Google Scholar 

  7. Twelves C, Wong A, Nowacki MP, Abt M, Burris H, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–704.

    Article  CAS  Google Scholar 

  8. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787–93.

    Article  CAS  Google Scholar 

  9. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping coloreetal tumors. J Clin Oncol. 2002;20:1043–8.

    Article  CAS  Google Scholar 

  10. SEER. Cancer stat facts: Colon and rectum cancer. [Internet]. SEER Cancer Stat Facts Color. Cancer. 2019. p. 2. Available from: https://seer.cancer.gov/statfacts/html/colorect.html.

  11. Sinclair AH, Schymura MJ, Boscoe FP, Yung RL, Chen K, Roohan P, et al. Measuring colorectal cancer care quality for the publicly insured in New York State. Cancer Med. 2012;1:363–71.

    Article  Google Scholar 

  12. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006;101:2308–18.

    Article  CAS  Google Scholar 

  13. Sanders T, Skevington S. Do bowel cancer patients participate in treatment decision-making? Findings from a qualitative study. Eur J Cancer Care (Engl). 2003;12:166–75.

    Article  CAS  Google Scholar 

  14. Benson AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004.22(16):3408–19. https://doi.org/10.1200/JCO.2004.05.063.

  15. Kumar A, Kennecke HF, Renouf DJ, Lim HJ, Gill S, Woods R, et al. Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer. Cancer. 2015;121:527–34.

    Article  Google Scholar 

  16. Kannarkatt J, Joseph J, Kurniali PC, Al-Janadi A, Hrinczenko B. Adjuvant chemotherapy for stage II colon cancer: A clinical dilemma. J Oncol Pract. 2017;13:233–41.

    Article  Google Scholar 

  17. Benson AB, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, version 1.2017: Clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw 2017. p. 370–98.

  18. Schofield PE, Butow PN, Thompson JF, Tattersall MHN, Beeney LJ, Dunn SM. Psychological responses of patients receiving a diagnosis of cancer. Ann Oncol. 2003;14:48–56.

    Article  CAS  Google Scholar 

  19. Mulders M, Vingerhoets A, Breed W. The impact of cancer and chemotherapy: Perceptual similarities and differences between cancer patients, nurses and physicians. Eur J Oncol Nurs. 2008;12:97–102.

    Article  Google Scholar 

  20. Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, et al. Prognostic Impact of Microsatellite Instability and DNA Ploidy in Human Colon Carcinoma Patients. Gastroenterology. 2006;131:729–37.

    Article  CAS  Google Scholar 

  21. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.

    Article  CAS  Google Scholar 

  22. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466–74.

    Article  CAS  Google Scholar 

  23. Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, et al. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst. 2012;104:1635–46.

    Article  CAS  Google Scholar 

  24. Parsons MT, Buchanan DD, Thompson B, Young JP, Spurdle AB. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet 2012; 151–7.

  25. Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant tre. J Clin Oncol. 2012;30:3353–60.

    Article  CAS  Google Scholar 

  26. Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer. JAMA Oncol [Internet]. cy;3:194. Available from: http://oncology.jamanetwork.com/article.aspx?doi = 10.1001/jamaoncol.2016.3797

  27. Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol. 2017;3(2):211–219. https://doi.org/10.1001/jamaoncol.2016.4227.

  28. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177–88.

    Article  CAS  Google Scholar 

  29. Taieb J, Taly V, Vernerey D, Bourreau C, Bennouna J, Faroux R, et al. Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration. Ann Oncol. 2019;30:v867.

    Article  Google Scholar 

  30. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med [Internet]. 2016;8:346ra92-346ra92. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27384348

Download references

Acknowledgments

We thank all of the participants for completing the questionnaire.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Medical Oncology, Afyon Health Sciences University School of Medicine, Afyonkarahisar, Turkey

    Ismail Beypinar, Hacer Demir & Meltem Baykara

  2. Department of Internal Medicine and Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey

    Murat Araz

  3. Department of Medical Oncology, İstinye University, Istanbul, Turkey

    Nuri Faruk Aykan

Authors
  1. Ismail Beypinar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hacer Demir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Murat Araz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meltem Baykara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nuri Faruk Aykan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ismail Beypinar.

Ethics declarations

Conflict of interest

None

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

ESM 1

(DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beypinar, I., Demir, H., Araz, M. et al. The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer. J Gastrointest Canc 53, 57–63 (2022). https://doi.org/10.1007/s12029-020-00542-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00542-5

Keywords

Search

Navigation